Formononetin (Synonyms: Biochanin B, NSC 93360) |
| Katalog-Nr.GN10527 |
Formononetin is a potent FGFR2 inhibitor with an IC50 of 4.3μM. Formononetin potently inhibits angiogenesis and tumor growth.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 485-72-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Formononetin is a potent FGFR2 inhibitor with an IC50 of 4.3μM. Formononetin potently inhibits angiogenesis and tumor growth[1].
Formononetin (10, 80μM; 3d) inhibit Ishikawa, HEC-1A, and HEC-251 cells proliferation in a dose-dependent manner[2]. Formononetin (10, 25μM; 24h) is a potent protectant against cisplatin-induced cell death through inhibiting intracellular ROS accumulation in pig kidney epithelial LLC-PK1 cells[3]. Formononetin (0.1, 0.3, 1μM; 30-60min) increased CNE2 cell estrogen receptor-α (ERα) and bcl-2, but decreased protein-phosphatase and tensin homologue (PTEN) protein expression[4].
In mice hyperoxic acute lung injury, Formononetin (10, 100 mg/kg; ip; 72h) significantly attenuated hyperoxia-induced elevated lung water content, up-regulation of pro-inflammatory cytokine levels, and increased lung neutrophil infiltration[5]. In mice acute ischaemic injury model, formononetin (20mg/kg; po; 28d) promoted the expression of ER β and p53 in a dose-dependent manner[6].
References:
[1] Wu X Y, Xu H, Wu Z F, et al. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models[J]. Oncotarget, 2015, 6(42): 44563.
[2]. Zhang Q, Huang X. The modulatory properties of Astragalus membranaceus treatment on endometrial cancer: an integrated pharmacological method[J]. PeerJ, 2021, 9: e11995.
[3] Lee H, Lee D, Kang K S, et al. Inhibition of intracellular ROS accumulation by Formononetin attenuates cisplatin-mediated apoptosis in LLC-PK1 cells[J]. International journal of molecular sciences, 2018, 19(3): 813.
[4] Guo Y H, Tang F Y, Wang Y, et al. Low concentration of Formononetin promotes proliferation of estrogen receptor-positive cells through an ERα-miR-375-PTEN-ERK1/2-bcl-2 pathway[J]. Oncotarget, 2017, 8(59): 100045.
[5]Chen Y, Wei D, Zhao J, et al. Reduction of hyperoxic acute lung injury in mice by Formononetin[J]. PloS one, 2021, 16(1): e0245050.
[6] Zhao L, Han J, Liu J, et al. A novel Formononetin derivative promotes anti-ischemic effects on acute ischemic injury in mice[J]. Frontiers in Microbiology, 2021, 12: 786464.
| Cell experiment [1]: | |
Cell lines | The Ishikawa, HEC-1A, and HEC-251 cell lines |
Preparation Method | The effect of Formononetin on the colony-forming ability of endometrial cancer cells was evaluated by colony formation assay. The Ishikawa, HEC-1A, and HEC-251 cell lines were seeded into 6-well plates at the concentration of 400 cells per well. After incubating for 24h at 37°C, the cells were incubated with Formononetin (40µM and 80µM). Three days later, most single colonies contain more than 50 cells. Cells were harvested and rinsed three times with distilled water, and images were obtained by a microscope. |
Reaction Conditions | 10, 80μM; 3d |
Applications | Formononetin inhibit Ishikawa, HEC-1A, and HEC-251 cells proliferation in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Hyperoxic acute lung injury Modle |
Preparation Method | Before the experiment, mice were housed in closed and individually ventilated cages under a 12h light:dark cycle for at least 1 week to acclimate to the environment. Mice had ad libitum access to standard chow and water. Mice were divided into a control group (room air+vehicle) and four other groups (room air+Formononetin, hyperoxia+vehicle, hyperoxia+Formononetin, and zinc protoporphyrin (ZnPP, an inhibitor of HO-1)+hyperoxia+Formononetin). To induce hyperoxic acute lung injury, mice were housed in closed cages and exposed to hyperoxia (>95% oxygen) for 72h. Room air exposure served as a control. |
Dosage form | 10, 100mg/kg; ip; 72h |
Applications | Formononetin pretreatment notably attenuated hyperoxia-induced elevating pulmonary water content, upregulation of proinflammatory cytokine levels and increasing infiltration of neutrophil in the lung. |
References: | |
| Cas No. | 485-72-3 | SDF | |
| Überlieferungen | Biochanin B, NSC 93360 | ||
| Chemical Name | 7-hydroxy-3-(4-methoxyphenyl)chromen-4-one | ||
| Canonical SMILES | COC1=CC=C(C=C1)C2=COC3=C(C2=O)C=CC(=C3)O | ||
| Formula | C16H12O4 | M.Wt | 268.27 |
| Löslichkeit | DMF: 30 mg/ml,DMF:PBS(pH 7.2)(1:1): 0.5 mg/ml,DMSO: 25 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.7276 mL | 18.6379 mL | 37.2759 mL |
| 5 mM | 745.5 μL | 3.7276 mL | 7.4552 mL |
| 10 mM | 372.8 μL | 1.8638 mL | 3.7276 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *